Analyst Ratings for Selecta Biosciences
Portfolio Pulse from Benzinga Insights
In the last quarter, Selecta Biosciences (NASDAQ:SELB) received 3 bullish and 1 indifferent ratings from analysts. The company's average 12-month price target is $3.25, a 27.78% decrease from the previous average price target of $4.50.
August 18, 2023 | 9:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Selecta Biosciences received mostly bullish ratings from analysts, but the decrease in the average price target could impact the stock negatively.
The bullish ratings indicate a positive outlook for the company. However, the decrease in the average price target suggests that analysts expect the stock price to decrease, which could negatively impact the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100